Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease

Authors:

Abstract
Parkinson disease (PD) is the second most common neurodegenerative disorder worldwide, causing motor and nonmotor symptoms, loss of dopamine, and accumulation of misfolded α-synuclein.1-3 Nilotinib hydrochloride is a multikinase inhibitor that preferentially targets Abelson (Abl)4-6 and discoidin domain receptors4-7 and effectively reduces misfolded proteins in several models of neurodegeneration.7 Nilotinib is approved in the United States for treatment of Philadelphia chromosome‒positive chronic myeloid leukemia at oral dosages of 300 mg twice daily.4-6 Several studies reported that low doses of nilotinib enter the brain and degrade α-synuclein and tau in animal models of neurodegeneration.7-11 A previous study suggested that nilotinib may increase dopamine metabolism and potentially treat motor and nonmotor symptoms of PD.12

This publication has 26 references indexed in Scilit: